Catamaran Corporation Reduces Overall Drug Trend to 2.4 Percent in 2013
Catamaran reports lower overall trend, record-setting generic dispensing
rate and greater cost controls
SCHAUMBURG, IL, April 16, 2014 /PRNewswire/ – Catamaran Corp. (NASDAQ: CTRX)
(TSX: CCT), a leading provider of pharmacy benefit management (PBM)
services and technology, released its 2014 Informed Trends(TM) report this morning. The report reveals a decrease in overall drug
trend, from 2.6 percent (2012) to 2.4 percent (2013), a record-setting
generic dispensing rate of 83.6 percent and progressive cost controls
for Catamaran clients. The report also shows a negative 0.7 percent
traditional trend driven by the adoption of generics for blockbuster
drugs such as Singular(®) and Lipitor(®).
“At Catamaran, we are enabling people to take charge of their health
through our ability to leverage data and technology in new and
innovative ways. This has allowed us to drive high levels of engagement
and better outcomes for all stakeholders,” said Mark Thierer, Chief
Executive Officer at Catamaran. “We view each unique touch point as a
moment of opportunity to make a difference – The Catamaran Difference.”
Specialty trend, led by increased utilization for multiple sclerosis and
other auto-immune diseases, was offset by a decrease in utilization for
hepatitis C drugs as patients awaited new drug approvals, resulting in
14.3 percent overall trend. Specialty is expected to represent nearly a
quarter of Catamaran’s total drug volume by 2016. To manage this
high-cost market segment, Catamaran’s specialty pharmacy, BriovaRx(TM),
takes a holistic approach to patient care offering hands-on,
individualized support to patients.
“Our top performing clients in 2013 were our most highly managed,
maximizing outcomes through our clinical programs across all market
segments,” said Sumit Dutta, M.D., MBA, Senior Vice President and Chief
Medical Officer at Catamaran. “We are delivering smarter solutions,
enabling critical connections and pioneering innovative interventions
to empower our clients and members to maximize their healthcare
Moments of Opportunity, the theme of the report, showcases how Catamaran harnesses every
opportunity to make a difference through personalized interventions and
tailored solutions for clients and members. The trend report breaks
down Catamaran’s clinical approach of engaging nationally, locally and
personally to create compelling results.
The full report, Moments of Opportunity, is available for download. High level insights can be found on the Catamaran trend portal and the company is also offering a webcast for a deeper understanding
of the key takeaways on Tuesday, April 22, 2014, at 12:30pm Eastern
time. To register, click here.
Catamaran, the industry’s fastest-growing pharmacy benefits manager,
helps organizations and the communities they serve take control of
prescription drug costs. Managing more than 350 million prescriptions
each year on behalf of over 32 million members, our flexible, holistic
solutions improve patient care and empower individuals to take charge
of their health. Processing one in every five prescription claims in
the U.S., Catamaran’s skill and scale deliver compelling financial
results and sustainable improvement in the overall health of members.
Catamaran is headquartered in Schaumburg, Ill., with multiple locations
in the U.S. and Canada. For more information, please visit CatamaranRx.com, and for industry news and information follow Catamaran on Twitter, @CatamaranCorp.